Key Findings:  Cannabis may be useful for symptom relief in Crohn's disease such as pain, nausea, and loss of appetite. However, studies with high methodological quality, sufficient sample size, and study duration are mandatory to determine potential therapeutic effects and risks of cannabis in gastroenterology. Currently, use of tetrahydrocannabinol to alleviate symptoms such as pain and appetite loss in Crohn's disease should only be considered in individual patients after failure of established medical therapies and only after careful risk-benefit assessment.
Type of Study:  Meta-analysis
Study Result:  Positive
Research Location(s):  Germany
Year of Pub:  2016
Cannabinoids Studied:  Cannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Citation:  Volz MS, et al. [Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review]. Schmerz. 2016; 30:37-46. doi: 10.1007/s00482-015-0087-0
Authors:  Volz MS, Siegmund B, Häuser W